CNS Response Announces Posters on rEEG(R) at the U.S. Psychiatric and Mental Health Congress
CNS Response, Inc. (OTCBB: CNSO), a life-sciences data company, today announced that five key scientific posters will be presented at the U.S. Psychiatric and Mental Health Congress, being held October 30 through November 1 at the San Diego Convention Center and Marriott Hotel & Marina. The posters are authored by thought leaders in psychiatry, addiction medicine and behavioral care management.
Additionally, CNS Response CEO Len Brandt will host a conference call Friday, November 7, at 2:00 p.m. Eastern (EST), to provide a corporate update and review of the significance of the five posters being presented at the U.S. Psychiatric and Mental Health Congress, and two third-party analyses of the economic and evidence-based benefits of rEEG. The conference call dial-in number for both U.S. and international callers is 480-629-9039. Please dial in to the conference five minutes before the call is scheduled to begin and ask the operator for the CNS Response call. An audio replay of the conference call will be available from November 7, at 5:00 p.m. Eastern (EST), until November 21, at 11:59 p.m. Eastern (EST). The replay can be accessed by dialing 303-590-3030 and entering conference number 3936802.
Posters to be presented in Booth 502 at the U.S. Psychiatric and Mental Health Congress
Poster #119, entitled “EEG Guided Medication Predictions in Treatment Refractory Eating Disorder Patients with Comorbid Depression: Opportunities for Personalized Medicine in Managed Healthcare,” is authored by James Greenblatt, M.D.; Craig Sussman, F.N.P.; and Mariko Jameson, B.S. The poster will be presented by Craig Sussman, FNP on October 30, at 3:45 p.m. to 6:45 p.m.
Poster #123, entitled “Referenced-EEG Guided Pharmacotherapy of Dual-Diagnosis Patients,” is authored by M. J. Schiller, M.D.; J. H. Shaffer, M.D.; and J. E. Milner, M.D. The poster will be presented by Mark Schiller, M.D. on October 30, at 3:45 p.m. to 6:45 p.m.
Poster #228, entitled “Referenced-EEG (rEEG) Guidance of Medications for Treatment Resistant Depressed Patients – A Pilot Study,” is authored by Charles DeBattista, M.D.; Daniel Hoffman, M.D.; Mark Schiller, M.D.; and Dan Iosifescu, M.D. The poster will be presented by Charles DeBattista, M.D. on October 31, at 3:45 p.m. to 6:45 p.m.
Poster #229, entitled “First Do No Harm: Children and SSRI’s,” is authored by Daniel Hoffman, M.D.; Mark Schiller, M.D.; and Len Brandt. The poster will be presented by Daniel Hoffman, M.D. on October 31, at 3:45 to 6:45 p.m.
Poster #230, entitled “Medication Washout: Imposing Discontinuation or A Diagnostic and Therapeutic Tool?,” is authored by Daniel Hoffman, M.D.; Charles DeBattista, M.D.; Gustavo Kinrys, M.D.; Jim Greenblatt, M.D.; and Mark Schiller, M.D. The poster will be presented by Daniel Hoffman, M.D. on October 31, at 3:45 p.m. to 6:45 p.m.
Third-Party Analysis Reports
Analysis Group Report: “Economic Impact of rEEG in Treatment Resistant Mental Health Conditions: Payer Perspective.”
United BioSource Corporation Report: “Comparing Levels of Evidence for Treatment of Treatment-Resistant Depression with rEEG(R) to Current Practice.”
About CNS Response
CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports (“rEEG(R) Reports”) that specifically guide physicians to treatment strategies based on the patient’s own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70 percent or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contact: Investor Relations: Marty Tullio McCloud Communications LLC 949.553.9748 Email Contact
SOURCE: CNS Response, Inc.